

Pulmonary Arterial Hypertension (PAH) Drugs Market Report by Drug Class (Endothelin Receptor Antagonists (ERAs), Vasodilators, Phosphodiesterase-5 (PDE-5) Inhibitors, Soluble Guanylate Cyclase (sGC) Stimulators, Calcium Channel Blockers (CCBs), Prostacyclin and Prostacyclin Analogs, and Others), Route of Administration (Inhalation, Injectable, Oral Administration), End User (Hospitals, Clinics, and Others), and Region 2024-2032

<https://marketpublishers.com/r/PD0EE4DBE648EN.html>

Date: April 2024

Pages: 146

Price: US\$ 3,899.00 (Single User License)

ID: PD0EE4DBE648EN

Abstracts

The global pulmonary arterial hypertension (PAH) drugs market size reached US\$ 7.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US\$ 11.6 Billion by 2032, exhibiting a growth rate (CAGR) of 4.6% during 2024-2032.

Pulmonary arterial hypertension (PAH) refers to a life-threatening medical condition characterized by high blood pressure in the arteries that connect the heart to the lungs. It causes the artery walls to tighten and narrow down, thereby exerting additional pressure on the heart to pump blood and weakening the muscles. In adverse cases, it can also compromise the heart's capacity to pump blood, thus eventually causing heart failure. PAH is characterized by shortness of breath, fatigue and swelling in ankles and legs. It is diagnosed through various tests, such as an echocardiogram, computer tomography (CT) scans, chest X-rays and ventilation-perfusion scans. It is usually treated using various drugs, such as endothelin receptor antagonists (ERAs), vasodilators, calcium channel blockers (CCBs), anticoagulants, diuretics and cardiac

glycosides. These drugs can be inhaled, injected or orally administered.

The increasing prevalence of cardiovascular and pulmonary disorders is one of the key factors driving the growth of the market. Furthermore, the rising geriatric population that is more susceptible to such medical ailments is providing a boost to the market growth. In line with this, changes in lifestyles, such as excessive alcohol consumption, a lack of physical activity, and unhealthy dietary patterns, have enhanced the risks of hypertension and high blood pressure. This, along with the development of novel orphan drugs and technologically advanced devices for the treatment of PAH, is favoring the market growth. Other factors, including increasing awareness among the masses regarding the available treatment alternatives for PAH, and improving healthcare infrastructure across the globe, are expected to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global pulmonary arterial hypertension (PAH) drugs market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on drug class, route of administration and end user.

Breakup by Drug Class:

- Endothelin Receptor Antagonists (ERAs)
- Vasodilators
- Phosphodiesterase-5 (PDE-5) Inhibitors
- Soluble Guanylate Cyclase (sGC) Stimulators
- Calcium Channel Blockers (CCBs)
- Prostacyclin and Prostacyclin Analogs
- Others

Breakup by Route of Administration:

- Inhalation
- Injectable
- Oral Administration

Breakup by End User:

- Hospitals
- Clinics

Others

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Actelion Pharmaceuticals Ltd (Johnson & Johnson), Arena Pharmaceuticals Inc., AstraZeneca PLC, Bayer Aktiengesellschaft, Daiichi Sankyo Company Limited, Gilead Science Inc., GlaxoSmithKline PLC, Merck KGaA, Novartis International AG, Pfizer Inc. and United Therapeutics Corporation.

Key Questions Answered in This Report

1. What was the size of the global Pulmonary Arterial Hypertension (PAH) drugs market

in 2023?

2. What is the expected growth rate of the global Pulmonary Arterial Hypertension (PAH) drugs market during 2024-2032?

3. What are the key factors driving the global Pulmonary Arterial Hypertension (PAH) drugs market?

4. What has been the impact of COVID-19 on the global Pulmonary Arterial Hypertension (PAH) drugs market?

5. What is the breakup of the global Pulmonary Arterial Hypertension (PAH) drugs market based on the drug class?

6. What is the breakup of the global Pulmonary Arterial Hypertension (PAH) drugs market based on the route of administration?

7. What are the key regions in the global Pulmonary Arterial Hypertension (PAH) drugs market?

8. Who are the key players/companies in the global Pulmonary Arterial Hypertension (PAH) drugs market?

Contents

1 PREFACE

2 SCOPE AND METHODOLOGY

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
 - 2.3.1 Primary Sources
 - 2.3.2 Secondary Sources
- 2.4 Market Estimation
 - 2.4.1 Bottom-Up Approach
 - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

3 EXECUTIVE SUMMARY

4 INTRODUCTION

- 4.1 Overview
- 4.2 Key Industry Trends

5 GLOBAL PULMONARY ARTERIAL HYPERTENSION (PAH) DRUGS MARKET

- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast

6 MARKET BREAKUP BY DRUG CLASS

- 6.1 Endothelin Receptor Antagonists (ERAs)
 - 6.1.1 Market Trends
 - 6.1.2 Market Forecast
- 6.2 Vasodilators
 - 6.2.1 Market Trends
 - 6.2.2 Market Forecast
- 6.3 Phosphodiesterase-5 (PDE-5) Inhibitors

- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Soluble Guanylate Cyclase (sGC) Stimulators
 - 6.4.1 Market Trends
 - 6.4.2 Market Forecast
- 6.5 Calcium Channel Blockers (CCBs)
 - 6.5.1 Market Trends
 - 6.5.2 Market Forecast
- 6.6 Prostacyclin and Prostacyclin Analogs
 - 6.6.1 Market Trends
 - 6.6.2 Market Forecast
- 6.7 Others
 - 6.7.1 Market Trends
 - 6.7.2 Market Forecast

7 MARKET BREAKUP BY ROUTE OF ADMINISTRATION

- 7.1 Inhalation
 - 7.1.1 Market Trends
 - 7.1.2 Market Forecast
- 7.2 Injectable
 - 7.2.1 Market Trends
 - 7.2.2 Market Forecast
- 7.3 Oral Administration
 - 7.3.1 Market Trends
 - 7.3.2 Market Forecast

8 MARKET BREAKUP BY END USER

- 8.1 Hospitals
 - 8.1.1 Market Trends
 - 8.1.2 Market Forecast
- 8.2 Clinics
 - 8.2.1 Market Trends
 - 8.2.2 Market Forecast
- 8.3 Others
 - 8.3.1 Market Trends
 - 8.3.2 Market Forecast

9 MARKET BREAKUP BY REGION

9.1 North America

9.1.1 United States

9.1.1.1 Market Trends

9.1.1.2 Market Forecast

9.1.2 Canada

9.1.2.1 Market Trends

9.1.2.2 Market Forecast

9.2 Asia Pacific

9.2.1 China

9.2.1.1 Market Trends

9.2.1.2 Market Forecast

9.2.2 Japan

9.2.2.1 Market Trends

9.2.2.2 Market Forecast

9.2.3 India

9.2.3.1 Market Trends

9.2.3.2 Market Forecast

9.2.4 South Korea

9.2.4.1 Market Trends

9.2.4.2 Market Forecast

9.2.5 Australia

9.2.5.1 Market Trends

9.2.5.2 Market Forecast

9.2.6 Indonesia

9.2.6.1 Market Trends

9.2.6.2 Market Forecast

9.2.7 Others

9.2.7.1 Market Trends

9.2.7.2 Market Forecast

9.3 Europe

9.3.1 Germany

9.3.1.1 Market Trends

9.3.1.2 Market Forecast

9.3.2 France

9.3.2.1 Market Trends

9.3.2.2 Market Forecast

9.3.3 United Kingdom

- 9.3.3.1 Market Trends
- 9.3.3.2 Market Forecast
- 9.3.4 Italy
 - 9.3.4.1 Market Trends
 - 9.3.4.2 Market Forecast
- 9.3.5 Spain
 - 9.3.5.1 Market Trends
 - 9.3.5.2 Market Forecast
- 9.3.6 Russia
 - 9.3.6.1 Market Trends
 - 9.3.6.2 Market Forecast
- 9.3.7 Others
 - 9.3.7.1 Market Trends
 - 9.3.7.2 Market Forecast
- 9.4 Latin America
 - 9.4.1 Brazil
 - 9.4.1.1 Market Trends
 - 9.4.1.2 Market Forecast
 - 9.4.2 Mexico
 - 9.4.2.1 Market Trends
 - 9.4.2.2 Market Forecast
 - 9.4.3 Others
 - 9.4.3.1 Market Trends
 - 9.4.3.2 Market Forecast
- 9.5 Middle East and Africa
 - 9.5.1 Market Trends
 - 9.5.2 Market Breakup by Country
 - 9.5.3 Market Forecast

10 SWOT ANALYSIS

- 10.1 Overview
- 10.2 Strengths
- 10.3 Weaknesses
- 10.4 Opportunities
- 10.5 Threats

11 VALUE CHAIN ANALYSIS

12 PORTERS FIVE FORCES ANALYSIS

- 12.1 Overview
- 12.2 Bargaining Power of Buyers
- 12.3 Bargaining Power of Suppliers
- 12.4 Degree of Competition
- 12.5 Threat of New Entrants
- 12.6 Threat of Substitutes

13 PRICE ANALYSIS

14 COMPETITIVE LANDSCAPE

- 14.1 Market Structure
- 14.2 Key Players
- 14.3 Profiles of Key Players
 - 14.3.1 Actelion Pharmaceuticals Ltd (Johnson & Johnson)
 - 14.3.1.1 Company Overview
 - 14.3.1.2 Product Portfolio
 - 14.3.2 Arena Pharmaceuticals Inc.
 - 14.3.2.1 Company Overview
 - 14.3.2.2 Product Portfolio
 - 14.3.2.3 Financials
 - 14.3.2.4 SWOT Analysis
 - 14.3.3 AstraZeneca PLC
 - 14.3.3.1 Company Overview
 - 14.3.3.2 Product Portfolio
 - 14.3.3.3 Financials
 - 14.3.3.4 SWOT Analysis
 - 14.3.4 Bayer Aktiengesellschaft
 - 14.3.4.1 Company Overview
 - 14.3.4.2 Product Portfolio
 - 14.3.4.3 Financials
 - 14.3.4.4 SWOT Analysis
 - 14.3.5 Daiichi Sankyo Company Limited
 - 14.3.5.1 Company Overview
 - 14.3.5.2 Product Portfolio
 - 14.3.5.3 Financials
 - 14.3.5.4 SWOT Analysis

- 14.3.6 Gilead Science Inc.
 - 14.3.6.1 Company Overview
 - 14.3.6.2 Product Portfolio
 - 14.3.6.3 Financials
 - 14.3.6.4 SWOT Analysis
- 14.3.7 GlaxoSmithKline PLC
 - 14.3.7.1 Company Overview
 - 14.3.7.2 Product Portfolio
 - 14.3.7.3 Financials
 - 14.3.7.4 SWOT Analysis
- 14.3.8 Merck KGaA
 - 14.3.8.1 Company Overview
 - 14.3.8.2 Product Portfolio
 - 14.3.8.3 Financials
 - 14.3.8.4 SWOT Analysis
- 14.3.9 Novartis International AG
 - 14.3.9.1 Company Overview
 - 14.3.9.2 Product Portfolio
- 14.3.10 Pfizer Inc.
 - 14.3.10.1 Company Overview
 - 14.3.10.2 Product Portfolio
 - 14.3.10.3 Financials
 - 14.3.10.4 SWOT Analysis
- 14.3.11 United Therapeutics Corporation
 - 14.3.11.1 Company Overview
 - 14.3.11.2 Product Portfolio
 - 14.3.11.3 Financials
 - 14.3.11.4 SWOT Analysis

List Of Tables

LIST OF TABLES

Table 1: Global: Pulmonary Arterial Hypertension Drugs Market: Key Industry Highlights, 2023 and 2032

Table 2: Global: Pulmonary Arterial Hypertension Drugs Market Forecast: Breakup by Drug Class (in Million US\$), 2024-2032

Table 3: Global: Pulmonary Arterial Hypertension Drugs Market Forecast: Breakup by Route of Administration (in Million US\$), 2024-2032

Table 4: Global: Pulmonary Arterial Hypertension Drugs Market Forecast: Breakup by End User (in Million US\$), 2024-2032

Table 5: Global: Pulmonary Arterial Hypertension Drugs Market Forecast: Breakup by Region (in Million US\$), 2024-2032

Table 6: Global: Pulmonary Arterial Hypertension Drugs Market Structure

Table 7: Global: Pulmonary Arterial Hypertension Drugs Market: Key Players

List Of Figures

LIST OF FIGURES

Figure 1: Global: Pulmonary Arterial Hypertension Drugs Market: Major Drivers and Challenges

Figure 2: Global: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Billion US\$), 2018-2023

Figure 3: Global: Pulmonary Arterial Hypertension Drugs Market: Breakup by Drug Class (in %), 2023

Figure 4: Global: Pulmonary Arterial Hypertension Drugs Market: Breakup by Route of Administration (in %), 2023

Figure 5: Global: Pulmonary Arterial Hypertension Drugs Market: Breakup by End User (in %), 2023

Figure 6: Global: Pulmonary Arterial Hypertension Drugs Market: Breakup by Region (in %), 2023

Figure 7: Global: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Billion US\$), 2024-2032

Figure 8: Global: Pulmonary Arterial Hypertension Drugs (Endothelin Receptor Antagonists - ERAs) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 9: Global: Pulmonary Arterial Hypertension Drugs (Endothelin Receptor Antagonists - ERAs) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 10: Global: Pulmonary Arterial Hypertension Drugs (Vasodilators) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 11: Global: Pulmonary Arterial Hypertension Drugs (Vasodilators) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 12: Global: Pulmonary Arterial Hypertension Drugs (Phosphodiesterase-5 - PDE-5 Inhibitors) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 13: Global: Pulmonary Arterial Hypertension Drugs (Phosphodiesterase-5 - PDE-5 Inhibitors) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 14: Global: Pulmonary Arterial Hypertension Drugs (Soluble Guanylate Cyclase-sGC Stimulators) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 15: Global: Pulmonary Arterial Hypertension Drugs (Soluble Guanylate Cyclase-sGC Stimulators) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 16: Global: Pulmonary Arterial Hypertension Drugs (Calcium Channel Blockers - CCBs) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 17: Global: Pulmonary Arterial Hypertension Drugs (Calcium Channel Blockers - CCBs) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 18: Global: Pulmonary Arterial Hypertension Drugs (Prostacyclin and

Prostacyclin Analogs) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 19: Global: Pulmonary Arterial Hypertension Drugs (Prostacyclin and Prostacyclin Analogs) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 20: Global: Pulmonary Arterial Hypertension Drugs (Other Drug Classes) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 21: Global: Pulmonary Arterial Hypertension Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 22: Global: Pulmonary Arterial Hypertension Drugs (Inhalation) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 23: Global: Pulmonary Arterial Hypertension Drugs (Inhalation) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 24: Global: Pulmonary Arterial Hypertension Drugs (Injectable) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 25: Global: Pulmonary Arterial Hypertension Drugs (Injectable) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 26: Global: Pulmonary Arterial Hypertension Drugs (Oral Administration) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 27: Global: Pulmonary Arterial Hypertension Drugs (Oral Administration) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 28: Global: Pulmonary Arterial Hypertension Drugs (Hospitals) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 29: Global: Pulmonary Arterial Hypertension Drugs (Hospitals) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 30: Global: Pulmonary Arterial Hypertension Drugs (Clinics) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 31: Global: Pulmonary Arterial Hypertension Drugs (Clinics) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 32: Global: Pulmonary Arterial Hypertension Drugs (Other End Users) Market: Sales Value (in Million US\$), 2018 & 2023

Figure 33: Global: Pulmonary Arterial Hypertension Drugs (Other End Users) Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 34: North America: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 35: North America: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 36: United States: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 37: United States: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 38: Canada: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 39: Canada: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 40: Asia Pacific: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 41: Asia Pacific: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 42: China: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 43: China: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 44: Japan: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 45: Japan: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 46: India: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 47: India: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 48: South Korea: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 49: South Korea: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 50: Australia: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 51: Australia: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 52: Indonesia: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 53: Indonesia: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 54: Others: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 55: Others: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 56: Europe: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 57: Europe: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales

Value (in Million US\$), 2024-2032

Figure 58: Germany: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 59: Germany: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 60: France: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 61: France: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 62: United Kingdom: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 63: United Kingdom: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 64: Italy: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 65: Italy: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 66: Spain: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 67: Spain: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 68: Russia: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 69: Russia: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 70: Others: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 71: Others: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 72: Latin America: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 73: Latin America: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 74: Brazil: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 75: Brazil: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 76: Mexico: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 77: Mexico: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 78: Others: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 79: Others: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 80: Middle East and Africa: Pulmonary Arterial Hypertension Drugs Market: Sales Value (in Million US\$), 2018 & 2023

Figure 81: Middle East and Africa: Pulmonary Arterial Hypertension Drugs Market Forecast: Sales Value (in Million US\$), 2024-2032

Figure 82: Global: Pulmonary Arterial Hypertension Drugs Industry: SWOT Analysis

Figure 83: Global: Pulmonary Arterial Hypertension Drugs Industry: Value Chain Analysis

Figure 84: Global: Pulmonary Arterial Hypertension Drugs Industry: Porter's Five Forces Analysis

I would like to order

Product name: Pulmonary Arterial Hypertension (PAH) Drugs Market Report by Drug Class (Endothelin Receptor Antagonists (ERAs), Vasodilators, Phosphodiesterase-5 (PDE-5) Inhibitors, Soluble Guanylate Cyclase (sGC) Stimulators, Calcium Channel Blockers (CCBs), Prostacyclin and Prostacyclin Analogs, and Others), Route of Administration (Inhalation, Injectable, Oral Administration), End User (Hospitals, Clinics, and Others), and Region 2024-2032

Product link: <https://marketpublishers.com/r/PD0EE4DBE648EN.html>

Price: US\$ 3,899.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PD0EE4DBE648EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms

& Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970